TVM Capital Life Science
Paul K. is currently working as an Analyst at TVM Capital Life Science and as a Research Fellow at Österreichische Gesundheitskasse. Previously, Paul has held various positions such as Visiting Associate at Boston Consulting Group, Medical Congress Support Member at medwhizz®, and Research Intern at Medical University of Vienna. Paul has also gained experience as a Thoracic Surgery Clinical Observer at Universitätsspital Zürich and as a Hand Surgery Clinical Observer at The Hand Clinic. Paul is pursuing a degree in Medicine at Ludwig-Maximilians-Universität München and has previously studied Medicine at Technical University of Munich. Additionally, Paul holds a Bachelor of Arts degree from the Music and Arts University of the City of Vienna.
This person is not in any offices
TVM Capital Life Science
TVM is a leading international venture capital firm focused on investing in life science innovations. The company has a highly experienced transatlantic investment team and approximately $900 million under management. TVM’s portfolio focuses on therapeutics and medical technologies from North America and the EU that represent differentiated first-in-class or best-in-class assets with the potential to transform standard of care. TVM pursues a unique two-pronged strategy, financing innovative early-stage therapeutics through a single asset company approach (Project-Focused Company, PFC) that leverages the firm’s strategic relationship with global pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated commercial-stage medical technologies and late clinical-stage therapeutics. The TVM investment team has worked together for over a decade to effectively utilize this innovative approach to maximize returns for investors and finance new therapies and technologies to meaningfully improve patient lives.